TrialThe Journal of clinical investigation1998

L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease.

J A Vita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.